The Filing Desk

Eton Pharmaceuticals vs ARS Pharmaceuticals

Eton Pharmaceuticals ETON · ARS Pharmaceuticals SPRY · Pharmaceuticals

ARS Pharmaceuticals reported revenue of $84 million in fiscal 2025, about the same as Eton Pharmaceuticals' $80 million in fiscal 2025. Eton Pharmaceuticals' revenue grew 104.9% in its latest year, and ARS Pharmaceuticals' fell 5.5%. Eton Pharmaceuticals had an operating margin of -1.1%, against -212.9% at ARS Pharmaceuticals. Free cash flow was $10 million at Eton Pharmaceuticals and −$171 million at ARS Pharmaceuticals.

Side by side

Eton PharmaceuticalsARS Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$80M$84M
Revenue growth104.9%−5.5%
Revenue growth a year, last 5 years——
Gross margin53.5%—
Operating margin−1.1%−212.9%
Net margin−5.8%−203.2%
Free cash flow$10M−$171M
Free cash flow margin12.8%−203.1%
Return on capital−1.9%—
Net debt to EBITDA1.4x—
Dividends and buybacks$0M$0M
Change in diluted share count3.9%−3.7%
Last close$61.36$3.36
P/E at the last close——
Insider trades, last 12 monthssold $25.2 millionsold $283,550
Piotroski F-score4 of 92 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Eton PharmaceuticalsARS Pharmaceuticals
Operating margin
Percent of revenue
Eton PharmaceuticalsARS Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Eton PharmaceuticalsARS Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Eton Pharmaceuticals and ARS Pharmaceuticals pages.